- Home
- CERS vs ITOS Comparison
CERS vs ITOS Comparison
Compare CERS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- ITOS
- Stock Information
- Founded
- CERS 1991
- ITOS 2011
- Country
- CERS United States
- ITOS United States
- Employees
- CERS N/A
- ITOS N/A
- Industry
- CERS EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CERS Technology
- ITOS Health Care
- Exchange
- CERS Nasdaq
- ITOS Nasdaq
- Market Cap
- CERS 286.0M
- ITOS 280.6M
- IPO Year
- CERS 1997
- ITOS 2020
- Fundamental
- Price
- CERS $1.83
- ITOS $8.03
- Analyst Decision
- CERS Buy
- ITOS Strong Buy
- Analyst Count
- CERS 3
- ITOS 3
- Target Price
- CERS $3.17
- ITOS $21.33
- AVG Volume (30 Days)
- CERS 1.4M
- ITOS 470.7K
- Earning Date
- CERS 03-04-2025
- ITOS 03-05-2025
- Dividend Yield
- CERS N/A
- ITOS N/A
- EPS Growth
- CERS N/A
- ITOS N/A
- EPS
- CERS N/A
- ITOS N/A
- Revenue
- CERS $176,229,000.00
- ITOS $35,000,000.00
- Revenue This Year
- CERS $21.42
- ITOS $271.18
- Revenue Next Year
- CERS $11.12
- ITOS N/A
- P/E Ratio
- CERS N/A
- ITOS N/A
- Revenue Growth
- CERS 14.71
- ITOS N/A
- 52 Week Low
- CERS $1.38
- ITOS $7.09
- 52 Week High
- CERS $2.59
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- CERS 60.59
- ITOS 54.92
- Support Level
- CERS $1.74
- ITOS $7.63
- Resistance Level
- CERS $1.89
- ITOS $8.09
- Average True Range (ATR)
- CERS 0.10
- ITOS 0.31
- MACD
- CERS 0.03
- ITOS 0.07
- Stochastic Oscillator
- CERS 89.74
- ITOS 78.07
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.